Affiliations 

  • 1 Geo-Bio-Environment Engineering and Innovation Laboratory, Molecular Engineering, Biotechnology and Innovation Team, Polydisciplinary Faculty of Taroudant, Ibn Zohr University, Agadir 80000, Morocco
  • 2 Microbial Biotechnology and Bioactive Molecules Laboratory, Sciences and Technologies Faculty, Sidi Mohmed Ben Abdellah University, P.O.Box-2002, Imouzzer Road, Fez, Morocco
  • 3 Health Research Center, Jazan University, P.O. Box: 114, Jazan 45142, Saudi Arabia. Electronic address: akahmed@jazanu.edu.sa
  • 4 Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
  • 5 High Institute of Nursing Professions and Health Techniques of Tetouan, Tetouan, Morocco
  • 6 Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat 10106, Morocco
  • 7 Department of Anatomy, Faculty of Medicine, Umm Alqura University, Makkah 21955, Saudi Arabia
  • 8 Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia
  • 9 School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia. Electronic address: ming.long@bath.edu
  • 10 Center of Disaster Monitoring and Earth Observation, Universitas Negeri Padang, Padang, Indonesia. Electronic address: fhrrazi@fmipa.unp.ac.id
Biomed Pharmacother, 2024 Aug;177:116886.
PMID: 38945700 DOI: 10.1016/j.biopha.2024.116886

Abstract

Colorectal cancer (CRC) is one of the most significant forms of human cancer. It is characterized by its heterogeneity because several molecular factors are involved in contiguity and can link it to others without having a linear correlation. Among the factors influencing tumor transformation in CRC, transforming growth factor-beta (TGF-β) plays a key promoter role. This factor is associated with human colorectal tumors with a very high prognosis: it increases the survival, invasion, and metastasis of CRC cells, thus functioning as an oncogene. The inhibition of this factor can constitute a major therapeutic route for CRC treatment. Various chemical drugs including synthetic molecules and biotherapies have been developed as TGF-β inhibitors. Moreover, the scientific community has recently shown a major interest in screening natural drugs inhibiting TGF-β in CRC. In this context, we carried out this review article using computerized databases, such as PubMed, Google Scholar, Springer Link, Science Direct, Cochrane Library, Embase, Web of Science, and Scopus, to highlight the molecular mechanism of TGF-β in CRC induction and progression and current advances in the pharmacodynamic effects of natural bioactive substances targeting TGF-β in CRC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.